The Lancet Just Renamed PCOS. For 170 Million Women, It Changes Everything

In early 2022, a 25-year-old woman who had been trying to conceive for eighteen months sat in a specialist’s office and heard the words “polycystic ovary syndrome” for the first time. She had never had an ovarian cyst. Her ultrasound was clean. What she did have was insulin resistance that no one had tested for, androgen levels nearly double the upper reference range, and a menstrual cycle that arrived maybe three times a year. She had spent a decade being told she just needed to lose weight. The name “PCOS” had hidden her condition from her — and from every GP she had seen since adolescence.

On May 12, 2026, after a global consensus process that took 14 years and involved 56 organizations across 32 countries, The Lancet published the document that finally fixed the name. Polycystic Ovary Syndrome is now Polyendocrine Metabolic Ovarian Syndrome — PMOS. The word “cystic” is gone. In its place are two words that actually describe what the condition is: a multisystem endocrine and metabolic disorder affecting an estimated 170 million women and people assigned female at birth worldwide. About 70 percent of those individuals are undiagnosed.

The Name That Hid a Disease

The term “polycystic ovary syndrome” entered the medical literature in 1935, when Irving Stein and Michael Leventhal published a case series of seven women who had enlarged ovaries, amenorrhea, and what they described as multiple ovarian cysts. The name stuck for 91 years. But what Stein and Leventhal called cysts were in fact immature ovarian follicles — a normal anatomical finding in the context of anovulation — and the name they chose embedded a misunderstanding that would shape clinical practice for nearly a century.

The new consensus process made the cost of that misunderstanding impossible to ignore. More than 22,000 patients and health professionals contributed survey responses, and the patient data revealed a consistent pattern of harm. Women described being told by family members that they “just had a few cysts” and shouldn’t worry. Others Googled the term and concluded they had ovarian cancer. Some delayed seeking care for years because the word “cystic” sounded either terrifying or trivial — and both reactions produced the same outcome: no action. The survey also surfaced a subtler harm: the name primed clinicians to focus on ovarian morphology, which led many to dismiss patients whose ultrasounds were normal even when the metabolic signs were screaming.

“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Helena Teede, the Monash University endocrinologist who led the consensus process, told EMJ Reviews. And in a separate interview she was blunter: “For too long, the name reduced a complex, long-term hormonal or endocrine disorder to a misunderstanding about ‘cysts’ and a focus on ovaries. This contributed to missed diagnoses and inadequate treatment.”

What PMOS Actually Is

The condition is not primarily a disorder of the ovaries. It is a multisystem endocrine and metabolic disturbance in which insulin resistance and compensatory hyperinsulinemia — present in roughly 85 percent of affected individuals, independent of body weight — drive androgen excess, ovulatory dysfunction, and lead to metabolic consequences. A 2024 review in Nature Reviews Endocrinology by Bulent Okan Yildiz established the condition as fundamentally a metabolic disease, noting that insulin resistance affects up to one in five women in some populations and that the hyperinsulinemic state directly stimulates ovarian androgen production. Yet because “ovary” was in the name, the standard workup rarely included metabolic screening unless the patient was actively trying to conceive. Fasting insulin, HOMA-IR, and lipid panels — cheap, routine tests — were simply not on the checklist for most patients.

The long-term stakes are high. Type 2 diabetes risk in PMOS runs two to four times higher than in the general population, and the condition is associated with elevated rates of cardiovascular disease, endometrial cancer, depression, and anxiety. It is the leading cause of anovulatory infertility. The metabolic features worsen with age: postmenopausal women with PMOS face a particularly steep cardiovascular risk profile that often goes unaddressed because the condition is still thought of as a reproductive-age disorder. For the teenager presenting with irregular periods, acne, and weight gain — the classic first presentation — the typical clinical response has been a birth-control prescription and no metabolic workup of any kind. The endocrine dimension was simply invisible under the old name.

Why the Name Change Matters

Terhi Piltonen, an endocrinologist at Oulu University Hospital in Finland and the international co-lead of the consensus, has argued that the renaming is not cosmetic. It is a clinical-practice lever. Under the old name, a referral to endocrinology was exceptional. Under PMOS, the metabolic and endocrine dimensions are in the label. The hope — grounded in the survey data showing that providers themselves were confused by the “cyst” terminology — is that the name itself redirects the diagnostic gaze.

Madhuri Patil, a clinician and president-elect of the Indian Society for Assisted Reproduction who participated in the consensus, described the shift as biologically accurate. “PMOS reflects the dysfunction of multiple hormonal systems, not just irregular ovulation,” she told the Indian Express. “It captures the full biological complexity of the disorder.”

But the implications go beyond individual clinicians. In India alone, an estimated 40 to 50 million women have the condition, and awareness levels lag far behind much of the developed world. Because PMOS is now legible as an endocrine and metabolic disorder — not just a gynecological one — it becomes eligible for research funding streams from endocrinology, cardiology, and metabolic-medicine bodies that had historically overlooked it. Conditions that affect predominantly women are, on average, less well-funded than those affecting men, and the gynecology-only framing reinforced that disparity. The new name cannot fix the funding gap on its own. But it removes one structural barrier to closing it.

Yet changing a name in The Lancet and changing what happens in a clinic in regional Queensland or rural Karnataka are two different things.

Making It Stick

The Lancet consensus is a multistep policy document — the kind of work that rarely makes headlines but can shift clinical practice more than any randomized trial. The process began in 2012 with an international evidence-based guideline, moved through two rounds of Delphi consensus involving 56 organizations and multiple waves of patient and provider surveys, and concluded with a formal recommendation to adopt PMOS across clinical guidelines, ICD coding, and medical education curricula. The methodology section of the paper is itself a contribution to the science of medical nomenclature: iterative, evidence-grounded, and built with the affected population participating at every stage.

Implementation will be slow. The International Classification of Diseases must be updated — a bureaucratic process that can take years. Medical school curricula need revision across hundreds of institutions. Professional societies spanning gynecology, endocrinology, and primary care must each issue updated guidelines. Patients — 170 million of them — must be told that the condition they thought they had now carries a different name. The authors of the consensus document acknowledge all of this directly, and they point to precedent. The shift from “impotence” to “erectile dysfunction” destigmatized a common condition and opened the door to primary-care management. Similarly, the shift from “mental retardation” to “intellectual disability” changed legal and educational frameworks around the condition. Nomenclature, when backed by institutional follow-through, can reshape care. The historical record shows this works.

For the 170 million people living with PMOS, the new name will not lower androgen levels or restore insulin sensitivity on its own. But what it can do — and what the consensus’s architects are betting on — is ensure that the next young woman who walks into a doctor’s office with irregular cycles, unexplained metabolic symptoms, and a decade of being told she just needs to lose weight gets a workup that looks at the whole picture, not just her ovaries. The condition didn’t change on May 12. The word for it finally did.

References

1. Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. https://doi.org/10.1016/S0140-6736(26)00717-8
2. Yildiz BO. Polycystic ovary syndrome as a metabolic disease. Nature Reviews Endocrinology. 2024. https://www.nature.com/articles/s41574-024-01057-w